이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

A First-in-human, Dose Escalation, and Expansion Study of BNT3211 for Participants With Advanced Solid Tumors

2026년 11월 16일 업데이트: BioNTech SE

A Phase I/II, First-in-human, Open-label, Multi-site, Dose Escalation and Expansion Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BNT3211 in Participants With Advanced Solid Tumors

This study is the first time BNT3211 will be tested in people. It will evaluate different dose levels of BNT3211 in adults to find suitable doses and to understand how safe the treatment is and how it may help people with advanced solid tumors.

연구 개요

상태

아직 모집하지 않음

정황

개입 / 치료

상세 설명

This study will consist of two parts (A and B). Part A will be a dose escalation to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BNT3211. Part B will be a dose optimization and proof-of-concept to further investigate the safety, tolerability and preliminarily antitumor activity of BNT3211 at doses selected from Part A. Part B will enroll participants with the same indications as in Part A.

No randomization will be performed in Part A. In Part B, for each selected indication, participants are randomized to the doses selected at the end of Part A using a dynamic allocation procedure.

There will be a screening period, a treatment period, and a follow-up period (including an end-of-treatment visit, a safety follow-up visit, and a survival follow-up period with regular visits).

Participants will receive BNT3211 until disease progression, start of new anticancer treatment, unacceptable toxicity, withdrawal of consent, or until the sponsor terminates the study or any other criterion for discontinuation is met.

연구 유형

중재적

등록 (추정된)

345

단계

  • 2 단계
  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

  • 이름: BioNTech clinical trials patient information
  • 전화번호: +49 6131 9084
  • 이메일: patients@biontech.de

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Key Inclusion Criteria:

  • Are ≥18 years of age (local laws will be followed if the age of consent is older).
  • Have an Eastern Cooperative Oncology Group performance status of 0 to 1.
  • Have a life expectancy of ≥3 months in the opinion of the investigator.
  • Have at least one measurable lesion as per RECIST v1.1.
  • Have an archival formalin-fixed paraffin-embedded tumor tissue sample available or are willing to be biopsied to obtain a fresh tumor tissue sample.
  • Have histologically or cytologically confirmed locally advanced, recurrent, or metastatic solid tumors and must have received all available standard of care (SoC) treatment in accordance with local practice (unless the standard therapy is considered inappropriate or intolerable) and failed at least first-line SoC therapy prior to enrollment.
  • Have an adequate coagulation, hematologic, and organ function as defined by the protocol.
  • Left ventricular ejection fraction (LVEF) ≥50% by either echocardiogram or multi-gated acquisition scan within 28 days prior to first dose of study treatment.

Key Exclusion Criteria:

  • Have had major surgery (not including diagnostic surgery) within the 4 weeks prior to the first dose of study treatment or are planned to undergo major surgery during the course of the study.

  • Have had prior allogeneic bone marrow transplantation or solid-organ transplantation.

  • Have had an inadequate washout period for prior anticancer treatment or other restricted medications prior to the first dose of investigational medicinal product (IMP) as defined in the protocol.

  • Have received systemic steroids (>10 mg/day of prednisone or its equivalent) or other immunosuppressive therapy within 2 weeks prior to the first dose of IMP. Protocol defined exceptions apply.

  • Have received any live or attenuated vaccine within 4 weeks prior to the first dose of IMP or intend to receive a live or attenuated vaccine during the study.

  • Have a history of leptomeningeal carcinomatosis.

  • Have brain metastases or spinal cord compression unless asymptomatic or treated and stable off steroids and anticonvulsants for at least 2 weeks prior to the first dose of IMP.

  • Have a history of (noninfectious) interstitial lung disease (ILD)/pneumonitis that requires steroids, current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening. Protocol-defined exceptions apply.

  • Have clinically significant concomitant pulmonary disease, including but not limited to: chronic obstructive pulmonary disease, restrictive lung disease, lung injury accompanied with autoimmune disease/connective tissue disorders.

  • Have uncontrolled pleural effusions, ascites, or pericardial effusions that require repeated drainage (once monthly or more frequently).

  • Have active gastric and duodenal ulcers, ulcerative colitis, or other gastrointestinal conditions that may cause bleeding or perforation in the opinion of the treating investigator.

  • Have an active infection that requires systemic therapy (except for oral antibiotics) within 1 week prior to the first dose of IMP. Participants receiving prophylactic anti-infective therapy (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) may be eligible.

  • Have active or chronic corneal disorders, or other active ocular conditions requiring ongoing therapy, or any clinically significant corneal disease that prevents adequate monitoring of drug-induced keratopathy.

  • Have a known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection. Protocol defined exceptions apply.

  • Have any other primary malignancy within 3 years prior to the first dose of IMP, except adequately resected non-melanoma skin cancer, curatively treated in situ disease, or other curatively treated solid tumors.

  • Have unresolved toxicities from previous anticancer therapy, defined as toxicities not yet resolved according to (US) National Cancer Institute Common Terminology Criteria for Adverse Events (AEs) Grade ≤1 (unless the investigator determines that certain AEs pose no safety risk to the participant, such as hair loss, Grade 2 peripheral neuropathy or stable hypothyroidism under hormone replacement therapy).

  • Have any of the following heart conditions within 6 months prior to the study treatment:

    • Acute coronary syndrome, coronary artery bypass grafting, congestive heart failure, aortic dissection, stroke, or other Grade 3 and above cardiovascular and cerebrovascular events.
    • New York Heart Association functional classification ≥II heart failure or LVEF <50%.
    • Ventricular arrhythmias requiring clinical intervention, second- to third-degree atrioventricular block, or congenital long QT syndrome. Participants with treated cardiac arrhythmia/atrial fibrillation are allowed.
    • Mean QT interval corrected by Fridericia's method >450 ms for males or >470 ms for females in three successive screening measurements based on a 12-lead electrocardiogram.
  • Unstable thrombotic event (e.g., deep vein thrombosis, arterial thrombosis, pulmonary embolism) requiring therapeutic intervention within 3 months.

Note: Other protocol defined inclusion and exclusion criteria apply.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위화되지 않음
  • 중재 모델: 순차적 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Part A (dose escalation) - BNT3211 monotherapy

Escalating dose levels of BNT3211.

Intravenous infusion

실험적: Part B (dose optimization) - BNT3211 monotherapy

Indications as in Part A. Doses will be selected from Part A.

Intravenous infusion

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Part A only - Occurrence of dose-limiting toxicities (DLTs) during the DLT evaluation period
기간: Up to 21 days from the initiation of first dose of BNT3211

DLT period defined as the first 21 days. Per dose level.

Up to 21 days from the initiation of first dose of BNT3211
Number of participants with treatment emergent adverse events (TEAEs), Grade ≥3 TEAEs, serious adverse events (SAEs), treatment-related TEAEs, treatment-related Grade ≥3 TEAEs, and treatment-related SAEs
기간: From first dose until 35 days after the last dose of BNT3211 (up to 36 months)

Per dose level (Part A) and per arm (Part B).

From first dose until 35 days after the last dose of BNT3211 (up to 36 months)
Number of participants with dose interruptions, reductions, or discontinuations of study treatment due to TEAEs
기간: From the first until the last dose of BNT3211 (up to 36 months)

Per dose level (Part A) and per arm (Part B).

From the first until the last dose of BNT3211 (up to 36 months)
Part B only - Objective response rate
기간: Up to 36 months

Defined as the proportion of participants with confirmed complete response (CR) or partial response (PR) (per the Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST v1.1] based on the investigator's assessment) is observed as best overall response. Per arm.

Up to 36 months

2차 결과 측정

결과 측정
측정값 설명
기간
PK assessment: Area under the curve (AUC) derived from serum concentrations of BNT3211, total antibody and unconjugated payload
기간: Up to approximately 35 days after the last dose of BNT3211 (up to 36 months)

After single- and multiple-dosing. Per dose level (Part A) and per arm (Part B). As data permits.

Up to approximately 35 days after the last dose of BNT3211 (up to 36 months)
PK assessment: Maximum concentration (Cmax) derived from serum concentrations of BNT3211, total antibody and unconjugated payload
기간: Up to approximately 35 days after the last dose of BNT3211 (up to 36 months)

After single- and multiple-dosing. Per dose level (Part A) and per arm (Part B). As data permits.

Up to approximately 35 days after the last dose of BNT3211 (up to 36 months)
PK assessment: Time to reach maximum (peak) serum concentration (Tmax) derived from serum concentrations of BNT3211, total antibody and unconjugated payload
기간: Up to approximately 35 days after the last dose of BNT3211 (up to 36 months)

After single- and multiple-dosing. Per dose level (Part A) and per arm (Part B). As data permits.

Up to approximately 35 days after the last dose of BNT3211 (up to 36 months)
PK assessment: Elimination half-life (t1/2) derived from serum concentrations of BNT3211, total antibody and unconjugated payload
기간: Up to approximately 35 days after the last dose of BNT3211 (up to 36 months)

After single- and multiple-dosing. Per dose level (Part A) and per arm (Part B). As data permits.

Up to approximately 35 days after the last dose of BNT3211 (up to 36 months)
Part A only - Objective response rate
기간: Up to 36 months

Defined as the proportion of participants with confirmed CR or PR (per RECIST v1.1 based on the investigator's assessment) is observed as best overall response. Per dose level.

Up to 36 months
Disease control rate
기간: Up to 36 months

Defined as the proportion of participants in whom a confirmed CR, confirmed PR or stable disease (SD) (per RECIST v1.1 based on the investigator's assessment, SD assessed at least 6 weeks [±7 days] after the first BNT3211 dose) is observed as best overall response. Per dose level (Part A) and per arm (Part B).

Up to 36 months
Duration of response
기간: Up to 36 months

Defined as the time from first objective response (CR or PR per RECIST v1.1 based on the investigator's assessment) to first occurrence of objective tumor progression (progressive disease per RECIST v1.1 based on the investigator's assessment) or death from any cause, whichever occurs first. Per dose level (Part A) and per arm (Part B).

Up to 36 months
Part B only - Progression free survival
기간: Up to 36 months

Defined as the time from first dose of BNT3211 to first objective tumor progression (PD per RECIST 1.1 based on the investigator's assessment), or death from any cause, whichever occurs first. Per arm.

Up to 36 months
Part B only - Overall survival
기간: Up to 36 months

Defined as the time from first dose of BNT3211 to death from any cause. Per arm.

Up to 36 months
Anti-drug antibody prevalence
기간: For up to 35 days from the last dose of BNT3211 (up to 36 months)

Defined as proportion of participants who are anti-drug antibody positive (either baseline or post-baseline). Per dose level (Part A) and per arm (Part B). As data permits.

For up to 35 days from the last dose of BNT3211 (up to 36 months)
Anti-drug antibody incidence
기간: For up to approximately 35 days from the last dose of BNT3211 (up to 36 months)

Defined as proportion of participants having treatment-emergent anti-drug antibodies. Per dose level (Part A) and per arm (Part B). As data permits.

For up to approximately 35 days from the last dose of BNT3211 (up to 36 months)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

수사관

  • 연구 책임자: BioNTech Responsible Person, BioNTech SE

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 11월 1일

기본 완료 (추정된)

2029년 10월 1일

연구 완료 (추정된)

2030년 3월 1일

연구 등록 날짜

최초 제출

2026년 11월 16일

QC 기준을 충족하는 최초 제출

2026년 11월 16일

처음 게시됨 (실제)

2026년 11월 20일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 20일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 16일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • BNT3211-01

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .